BRTX (BioRestorative Therapies) EBIT: $-14.23 Mil (TTM As of Mar. 2026)


BRTX BioRestorative Therapies Inc BRTX
51 GF Score
Price $0.39
GF Value $1.52
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies EBIT?

BioRestorative Therapies BRTX -2.32% 51 EBIT is $-14.23 Mil as of Mar. 2026. GuruFocus rates BRTX with a GF Score™ of 51/100 and a GF Value™ of $1.52 (Possible Value Trap). The stock has 3 warning signs investors should review.

BioRestorative Therapies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.39 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioRestorative Therapies's annualized ROC % for the quarter that ended in Mar. 2026 was -583.54%. BioRestorative Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3,937.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioRestorative Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 452.59%.

BioRestorative Therapies  (NAS:BRTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioRestorative Therapies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-13.544 * ( 1 - 0% )/( (3.056 + 1.586)/ 2 )
=-13.544/2.321
=-583.54 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.08 - 1.61 - ( 2.953 - max(0, 3.723 - 3.137+2.953))
=3.056

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.64 - 0.869 - ( 3.592 - max(0, 1.615 - 3.8+3.592))
=1.586

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

BioRestorative Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.544/( ( (0.359 + max(-3.539, 0)) + (0.329 + max(-1.407, 0)) )/ 2 )
=-13.544/( ( 0.359 + 0.329 )/ 2 )
=-13.544/0.344
=-3,937.21 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.016 + 0 + 0.168) - (1.61 + 0 + 2.113)
=-3.539

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.013 + 0 + 0.195) - (0.869 + 0 + 0.746)
=-1.407

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioRestorative Therapies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-14.225/-3.143
=452.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies EBIT Related Terms

BioRestorative Therapies EBIT Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies EBIT Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.31 -18.86 -15.14 -11.56 -15.65

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.81 -3.31 -3.71 -3.83 -3.39

BRTX vs KPRX, INTS, ERNA: EBIT Comparison

For the Biotechnology subindustry, BioRestorative Therapies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's EV-to-EBIT falls into.


BRTX
51GF Score
BioRestorative Therapies Inc BRTX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-14.23 Mil mean?
BioRestorative Therapies (BRTX) has a EBIT of $-14.23 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioRestorative Therapies.
Is BioRestorative Therapies' EBIT too high?
BioRestorative Therapies' current EBIT is $-14.23 Mil. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' EBIT compare to KPRX and INTS?
BioRestorative Therapies' EBIT of $-14.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioRestorative Therapies. BioRestorative Therapies's current EBIT is $-14.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (BRTX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.52, compared to a current price of $0.39 — trading 74.5% below its estimated fair value. The current EBIT is $-14.23 Mil. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioRestorative Therapies (BRTX), the current EBIT is $-14.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (BRTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of $0.39 is trading 74.5% below its estimated GF Value™ of $1.52. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for BRTX:

  • EBIT: $-14.23 Mil
  • GF Value™: $1.52 vs. price of $0.39 (74.5% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges 9OF:Germany
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for BRTX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$1.52
GF Value